Intraluminal Brachytherapy after Metallic Stent Placement in Primary Bile Duct Carcinoma.
10.3348/jkrs.2001.44.6.675
- Author:
Kyu Hong PARK
1
;
Soon Gu CHO
;
Sung Gwon KANG
;
Don Haeng LEE
;
Woo Cheol KIM
;
Keon Young LEE
;
Chang Hae SUH
Author Information
1. Department of Radiology, Inha University College of Medicine.
- Publication Type:Original Article
- Keywords:
Bile ducts,interventional procedure;
Bile ducts, neoplasms;
Bile ducts,stents and prostheses;
Bile ducts, stenosis or obstruction;
Bile ducts, therapeutic radiology
- MeSH:
Bile Ducts*;
Bile*;
Brachytherapy*;
Humans;
Stents*
- From:Journal of the Korean Radiological Society
2001;44(6):675-682
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To determine the effect of intraluminal brachytherapy on stent patency and survival after metallic stent placement in patients with primary bile duct carcinoma. MATERIALS AND METHODS: Twenty-seven patients with primary bile duct carcinoma underwent metallic stent placement; in 16 of the 27 intraluminal brachytherapy with an iridium-192 source (dose, 25 Gy) was the performed. Obstruction was due to either hilar (n=14) or non-hilar involvement (n=13). For statistical comparison of patients who underwent/did not undergo intraluminal brachytherapy, stent patency and survival were calculated using the Kaplan-Meier method and an independent t test. RESULTS: The mean durations of stent patency and survival were 9.1 and 10.0 months respectively in patients who underwent intraluminal brachytherapy, and 4.2 and 5.0 months in those who did not undergo this procedure (p<0.05). The mean durations of stent patency and survival among the 22 patients who died were 7.6 (range, 0.8 -16.1) and 8.3 (range, 0.8-17.3) months, respectively, in the eleven patients who underwent intraluminal brachytherapy, and 4.2 (range, 0.9-8.0) and 5.0 (range, 0.9-8.4) months in those whom the procedure was not performed (p<0.05). CONCLUSION: Intraluminal brachytherapy after stent placement extended both stent patency and survival in patients with primary bile duct carcinoma.
